In Brief

Valeant acquires iNova, closes Afexa deal; CRN says FDA’s proposed rule on gifts “goes too far”; Kentucky bill would strengthen PSE limits; and more OTC drug and nutritional product market news In Brief

Valeant Pharmaceuticals International Inc. will acquire OTC and pharmaceutical firm iNova Pharmaceuticals Pty. Ltd. for $625 million Australian ($615 million U.S.) upfront. iNova markets OTCs in Australia, New Zealand, Southeast Asia and South Africa. Its portfolio includes cold and flu remedies Difflam and Duro Tuss. Valeant could pay up to an additional $73.9 million for iNova depending on the success of iNova’s Rx pipeline. The deal “transforms our operations in the Australian market” and provides “a beachhead in both Southeast Asia and South Africa,” Valeant CEO J. Michael Pearson said in a Nov. 20 release.

Mississauga, Ontario-based Valeant Nov. 16 said it will cut staff and review alternatives for its research and development unit as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Spain’s Medicines Shortages Plan Clears Administrative Hurdles For Essential Medicine Manufacturers

 

A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.

EU Industry Proposes 3-Basket Strategy To Phase Out Animal Testing

 

A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By 

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

More from Geography

EU Industry Proposes 3-Basket Strategy To Phase Out Animal Testing

 

A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.

Consumer Groups Have A ‘Radical Transparency’ List For US FDA’s PDUFA VIII

 

Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.